Pulmonary Embolism (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism (Cardiovascular) – Drugs In Development, 2021, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism (Cardiovascular) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively.

Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Acticor Biotech SAS

Bio-Synectics Inc

China Resources Emde Biological Pharmaceutical Co Ltd

Indiana Lysis Technologies LLC

Kolmar Korea Co Ltd

Les Laboratoires Servier SAS

Supergene LLC

Tasly Pharmaceutical Group Co Ltd

Techfields Pharma Co Ltd

Tianjin Pharmaceuticals Group Co Ltd

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pulmonary Embolism - Overview

Pulmonary Embolism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pulmonary Embolism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pulmonary Embolism - Companies Involved in Therapeutics Development

Acticor Biotech SAS

Bio-Synectics Inc

China Resources Emde Biological Pharmaceutical Co Ltd

Indiana Lysis Technologies LLC

Kolmar Korea Co Ltd

Les Laboratoires Servier SAS

Supergene LLC

Tasly Pharmaceutical Group Co Ltd

Techfields Pharma Co Ltd

Tianjin Pharmaceuticals Group Co Ltd

Verseon Corp

Pulmonary Embolism - Drug Profiles

BS-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Pulmonary Embolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glenzocimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKM-183A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reteplase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-62798 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Staphylokinase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TF-0023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

urokinase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-2851 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zifa-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pulmonary Embolism - Dormant Projects

Pulmonary Embolism - Discontinued Products

Pulmonary Embolism - Product Development Milestones

Featured News & Press Releases

Oct 25, 2017: IU-based drug-discovery startup aims to use nanotechnology to digest blood clots in lungs

Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pulmonary Embolism, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pulmonary Embolism – Pipeline by Acticor Biotech SAS, 2021

Pulmonary Embolism – Pipeline by Bio-Synectics Inc, 2021

Pulmonary Embolism – Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2021

Pulmonary Embolism – Pipeline by Indiana Lysis Technologies LLC, 2021

Pulmonary Embolism – Pipeline by Kolmar Korea Co Ltd, 2021

Pulmonary Embolism – Pipeline by Les Laboratoires Servier SAS, 2021

Pulmonary Embolism – Pipeline by Supergene LLC, 2021

Pulmonary Embolism – Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021

Pulmonary Embolism – Pipeline by Techfields Pharma Co Ltd, 2021

Pulmonary Embolism – Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2021

Pulmonary Embolism – Pipeline by Verseon Corp, 2021

Pulmonary Embolism – Dormant Projects, 2021

Pulmonary Embolism – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Pulmonary Embolism, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports